Edition:
India

Adverum Biotechnologies Inc (ADVM.OQ)

ADVM.OQ on NASDAQ Stock Exchange Global Market

3.15USD
2:29am IST
Change (% chg)

$-0.15 (-4.55%)
Prev Close
$3.30
Open
$3.35
Day's High
$3.35
Day's Low
$3.15
Volume
37,675
Avg. Vol
48,124
52-wk High
$4.20
52-wk Low
$2.45

Latest Key Developments (Source: Significant Developments)

Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies
Thursday, 7 Dec 2017 

Dec 6 (Reuters) - Adverum Biotechnologies Inc ::HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING.  Full Article

Adverum Begins Patient Enrollment In Advance Phase 1/2 Clinical Trial
Tuesday, 5 Dec 2017 

Dec 5 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES BEGINS PATIENT ENROLLMENT IN THE ADVANCE PHASE 1/2 CLINICAL TRIAL FOR A1AT DEFICIENCY.ADVERUM BIOTECHNOLOGIES INC - ‍COMPANY EXPECTS TO REPORT PRELIMINARY DATA IN SECOND HALF OF 2018​.  Full Article

‍Adage Capital Partners Reports A 5.55 Percent Passive Stake In Adverum Biotechnologies As Of Nov 17, 2017
Monday, 27 Nov 2017 

Nov 27 (Reuters) - Adverum Biotechnologies Inc ::‍ADAGE CAPITAL PARTNERS GP, L.L.C REPORTS A 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF NOVEMBER 17, 2017 - SEC FILING​.  Full Article

Adverum Biotechnologies posts Q3 loss of $0.32 per share
Thursday, 9 Nov 2017 

Nov 8 (Reuters) - Adverum Biotechnologies Inc :Adverum biotechnologies reports third quarter 2017 financial results and provides corporate update.Q3 loss per share $0.32.Q3 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S.Adverum biotechnologies - ‍cash, cash equivalents,marketable securities were $186.6 million as of sept 30, 2017, versus $197.4 million as of june 30, 2017 ​.Adverum biotechnologies - ‍current cash position expected to fund 3 lead gene therapy programs through end of 2019.  Full Article

Adverum Biotechnologies files for mixed shelf of up to $150 mln
Friday, 11 Aug 2017 

Aug 10 (Reuters) - Adverum Biotechnologies Inc -:Adverum Biotechnologies Inc files for mixed shelf of up to $150 million - ‍​sec filing.  Full Article

Adverum Biotechnologies provides update on Alpha-1 antitrypsin deficiency program
Friday, 14 Oct 2016 

Adverum Biotechnologies Inc : Adverum Biotechnologies provides update on alpha-1 antitrypsin deficiency program . Expects to begin enrolment of patients in phase 1/2 clinical trial for advm-043 in Q4 of 2017. . Adverum Biotechnologies Inc - decided to upgrade advm-043 manufacturing process by implementing its proprietary baculovirus-based production system . Adverum Biotechnologies Inc - company now expects to begin enrolment of patients in phase 1/2 clinical trial for advm-043 in Q4 of 2017 . Plans to transfer third-party contract manufacturing for advm-043 to a large-scale contract manufacturer . Adverum Biotechnologies Inc - goal is to meet with FDA to review modified plans in Q1 of 2017 .Adverum Biotechnologies - other lead programs for wamd and hae remain on target to initiate toxicology studies in first half of 2017.  Full Article

Adverum biotechnologies, inc. announces new executive chair and CEO
Friday, 14 Oct 2016 

Adverum Biotechnologies Inc : Adverum Biotechnologies, Inc. announces new executive chair and CEO . Says Amber Salzman appointed CEO .Adverum Biotechnologies Inc says Paul B. Cleveland has been appointed executive chairman of board.  Full Article

Adverum Biotechnologies posts Q2 loss per share $1.76
Wednesday, 10 Aug 2016 

Adverum Biotechnologies Inc : Adverum Biotechnologies Inc reports second quarter 2016 financial results . Q2 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S .Q2 loss per share $1.76.  Full Article

Adverum Biotechnologies and Editas Medicine announce collaboration
Tuesday, 9 Aug 2016 

Adverum Biotechnologies Inc : Editas will also pay an additional option exercise fee of $1 million for an exclusive license to Adverum's AAV vectors . Is eligible to get development, commercial milestone payments, royalties on any resulting commercialized Editas products . Adverum biotechnologies and Editas Medicine announce collaboration to explore delivery of genome editing medicines to eye .Editas will pay Adverum an upfront fee of $1 million.  Full Article

Adverum Biotechnologies appoints Leone Patterson as CFO
Monday, 13 Jun 2016 

Adverum Biotechnologies Inc : Leone Patterson has been appointed as company's chief financial officer - SEC filing . Patterson will also assume duties of company's principal financial officer. .Patterson served as chief financial officer of diadexus, inc. From march 2015 to june 2016.  Full Article

BRIEF-Highbridge Capital Reports 5.55 Pct Passive Stake In Adverum Biotechnologies

* HIGHBRIDGE CAPITAL MANAGEMENT LLC REPORTS 5.55 PERCENT PASSIVE STAKE IN ADVERUM BIOTECHNOLOGIES INC AS OF DECEMBER 5 - SEC FILING Source text for Eikon: (http://bit.ly/2iwSEnw) Further company coverage: